Approval · Notice of Compliance 32802 · 2024
THALOMID: Notice of Compliance 32802
Issued March 1, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32802
- Date
- March 1, 2024
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Change in Product Ownership
Products in this notice
Medicinal ingredients
- THALIDOMIDE 50 MG per CAP
- THALIDOMIDE 100 MG per CAP
- THALIDOMIDE 200 MG per CAP